SSP buyout to bolster Boehringer Ingelheim's Japanese OTC presence
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim is planning to acquire 100% of its already majority-owned Japanese subsidiary, SSP, through a tender offer valuing the buyout at around ¥82.2 billion ($917.4 million) should it be successful.